Reviewed by Peptide Treatments Medical Advisory Board
Ipamorelin: Side Effects & Safety
Known side effects, safety considerations, and adverse reaction data for Ipamorelin.
Back to Ipamorelin overviewData source: Side effect data comes from clinical trials, preclinical research, and anecdotal reports. No FDA-approved labeling exists for this compound.
Reported Side Effects (6 items)
| # | Side Effect |
|---|---|
| 1 | Injection site reactions — redness, swelling, or mild pain at the subcutaneous injection site (~10%) |
| 2 | Transient headache — most commonly reported adverse event (~5-8%) |
| 3 | Nausea — rare, typically mild and self-limiting |
| 4 | Flushing — rare vasomotor effects reported shortly after injection |
| 5 | Blood sugar effects — GH opposes insulin action; potential glucose elevation in insulin-resistant individuals |
| 6 | Limited long-term human safety data — Phase II trials showed safety up to 7 days; chronic use is not well characterized |
Known Drug Interactions
Important: Only documented and contraindicated interactions are shown here. View all interactions including theoretical →
| Drug | Classification | Mechanism |
|---|---|---|
| glucocorticoids | Documented | May reduce GH secretagogue effect by suppressing GH axis |
| somatostatin analogs | Documented | Directly opposes ghrelin-mimetic action |